Selection of exams at diagnosis and during follow-up according to the risk of disease progression.

<p>Selection of exams at diagnosis and during follow-up according to the risk of disease progression.</p

Tumor characteristics considered relevant to classify patients at high risk of disease progression.

<p>Tumor characteristics considered relevant to classify patients at high risk of disease progression.</p

Selection of exams independently of the risk of disease relapse.

<p>Selection of exams independently of the risk of disease relapse.</p

Risk of bias summary.

<p>Legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069269#pone-0069269-g002" target="_blank">Figure 2</a>. Reviewers’ judgment on each “Risk of bias” item within each included study.</p

Forest plot of vitamin D supplementation and breast cancer incidence.

<p>Legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069269#pone-0069269-g003" target="_blank">Figure 3</a>. M–H, Mantel-Haenszel; 95% CI, 95% confidence interval; df, degrees of freedom.</p

Characteristics of the included Randomized Clinical Trials (RCTs).

<p>Characteristics of the included Randomized Clinical Trials (RCTs).</p

Forest plot of vitamin D supplementation and breast cancer incidence.

<p>Administration mode on treatment effects. Legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069269#pone-0069269-g004" target="_blank">Figure 4</a>. M–H, Mantel-Haenszel; 95% CI, 95% confidence interval; df, degrees of freedom.</p

Additional file 2: Table S2. of Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy

associations between TAZ/YAP, assessed in the tumor and in the microenvironment, and clinical-molecular features and pCR (N = 61). (DOCX 12 kb

Additional file 1: Table S1. of Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy

Expression of TAZ and YAP in cancer cells, non-lymphocytic stromal cells, endothelial cells, and tumor-infiltrating lymphocytes. Subcellular localization of TAZ/YAP in tumors is also reported (N = 61). (DOCX 13 kb

Additional file 3: Table S3. of Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy

Pattern of recurrence in the 19 TNBC patients. (DOCX 12 kb